Periprocedural management of anticoagulation for atrial fibrillation catheter ablation in direct oral anticoagulant-treated patients.
Anne-Céline MartinSarah LessireIsabelle LeblancAnne-Sophie DincqIvan PhilipIsabelle Gouin-ThibaultAnne GodierPublished in: Clinical cardiology (2018)
Our data showed that uninterrupted DOAC therapy resulted in an unpredictable and highly variable initial level of anticoagulation before catheter ablation. Moreover, even with DOAC interruption preventing interference between DOAC, UFH, and ACT, intraprocedural UFH monitoring was complex. Altogether, our exploratory results call into question the appropriateness of transposing UFH dose protocols, as well as the relevance of ACT monitoring in uninterrupted DOAC-treated patients.
Keyphrases
- atrial fibrillation
- catheter ablation
- direct oral anticoagulants
- left atrial
- venous thromboembolism
- left atrial appendage
- oral anticoagulants
- end stage renal disease
- newly diagnosed
- ejection fraction
- percutaneous coronary intervention
- peritoneal dialysis
- heart failure
- chronic kidney disease
- stem cells
- prognostic factors
- machine learning
- deep learning
- coronary artery disease
- patient reported
- acute coronary syndrome